| Title |
Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD
|
|---|---|
| Published in |
Current Treatment Options in Gastroenterology, January 2014
|
| DOI | 10.1007/s11938-013-0005-4 |
| Pubmed ID | |
| Authors |
Reena Khanna, Brian G. Feagan |
| Abstract |
Although tumor necrosis factor (TNF)-antagonists are highly effective agents for the treatment of inflammatory bowel diseases (IBD), up to 40 % of patients ultimately lose response. As a result of the limited availability of treatment options, empiric dose escalation or switching of TNF-antagonists have evolved as strategies to regain response. Recently, therapeutic drug monitoring (TDM) (measurement of serum drug and antidrug antibody concentrations) has emerged to facilitate informed decision-making in patients with secondary loss of response to a TNF-antagonist. The evidence supporting the use of TDM in clinical practice and future applications of this approach will be discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 14% |
| Unknown | 6 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 29% |
| Student > Master | 2 | 29% |
| Other | 1 | 14% |
| Researcher | 1 | 14% |
| Unknown | 1 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 71% |
| Computer Science | 1 | 14% |
| Engineering | 1 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2014.
All research outputs
#18,360,179
of 22,739,983 outputs
Outputs from Current Treatment Options in Gastroenterology
#195
of 266 outputs
Outputs of similar age
#228,637
of 304,595 outputs
Outputs of similar age from Current Treatment Options in Gastroenterology
#4
of 7 outputs
Altmetric has tracked 22,739,983 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 266 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,595 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.